Hibridna emisijska/transmisijska tomografija (SPECT/CT) somatostatinskih receptora u dijagnostici neuroendokrinih tumora

Autor: Maršić, Matej
Přispěvatelé: Grbac-Ivanković, Svjetlana
Jazyk: chorvatština
Rok vydání: 2016
Předmět:
Popis: Ovaj rad obuhvaća analizu 122 pacijenta sa 163 pretrage 99mTc-Tektrotydom® SPECT/CT tehnologijom u periodu od 12.10.2012. do 17.12.2015. Svi podaci uzimani su retrospektivno. Važniji rezultati općih podataka pokazuju: stalan porast broja pacijenata; pacijente na pretrazi čini 55% žena i 45% muškaraca; velik broj pacijenata na pretrazi nakon navršene 50. godine (91% ima 50 godina ili više); prosječna dob pacijenta na pretrazi 62,3 godine. Dobiveni su i podaci koji su u užem smislu medicinski: 60% pacijenata na pretragu je uputio onkolog; 21 pacijent je imao potvrđenu patohistološku dijagnozu NET-a, uz napomenu da podaci nisu bili dostupni za sve pacijente. PET/CT nalaz imalo je 21% pacijenata, uz napomenu da su podaci analizirani samo ako je pacijent donio fotokopirani PET/CT nalaz, a nadležni liječnik ga je spremio u karton. Prosječni broj dana od PET/CT do SPECT/CT snimanja iznosio je 120 dana, a medijan 65,5 dana. PET/CT i SPECT/CT akumulacije u lezijama se poklapaju u 43% kod solitarnih i u 48% kod multiplih lezija. PET tehnologija je zabilježila veći broj akumulirajućih lezija nego SPECT. U skupini pacijenata s više lezija 31% lezija je vidljivo PET-om, a ne SPECT-om. Osjetljivost SPECT-a s 99mTc-Tektrotydom® u ovom radu iznosi 71%. Postotak pacijenata s proširenom bolešću (prema SPECT snimanju) iznosio je 30%, a od tog postotka 36% pacijenata je imalo PET/CT nalaz. Dvije najčešće pretrage preporučene nakon snimanja su MR i/ili CT te PET/CT. Nalaz kromogranina A u krvi imalo je 41% pacijenata. Od 39 pacijenata s povišenim kromograninom A 38% imalo je patološku akumulaciju u SPECT/CT nalazu. This paper was based on 122 patients with 163 imagings with 99mTc-Tektrotyd® SPECT/CT from 12/10/2012 to 17/12/2015. All the data were collected retrospectively. General data show: constant increasing number of patients; patients on imaging were 55% women and 45% men; majority of patients older than 50 (91% of patients are 50 or older); average age of patients on imaging is 62,3. There are also data that are medical in the strict sense. Oncologists sent 60% of the patients. Histopathological diagnosis of NET was found in 21 patient, noting that the data were not available for all the patients. In 21% of patients PET/CT was performed, noting that this information was recorded only if the patient brought a copy of a PET/CT finding to the doctor, and it was archived. Elapsed time between PET/CT and SPECT/CT was 120 days, and the median was 65,5 days. Lesions with accumulation were concordant in PET/CT and SPECT/CT imaging comprised 43% of the cases with solitary lesions, and 48% of the multiple lesions. By PET/CT imaging more positive lesions were registered than by SPECT/CT. In the group of patients with multiple lesions there were 31% of accumulating lesions that were visible in PET/CT, but not in SPECT/CT. Sensitivity of SPECT with s 99mTc-Tektrotyd® was 71%. According to the accumulations in SPECT/CT there were 30% of patients with advanced disease, of which 36% had PET/CT. Most frequent tests recommended were MR and/or CT and PET/CT. Results show that 41% of patients had chromogranin A levels determined. There were 39 patients with elevated chromogranin A levels, of which 38% had a pathologic accumulation visible on SPECT/CT.
Databáze: OpenAIRE
Externí odkaz: